Ofatumumab
| Generic name | Ofatumumab |
| Pronunciation | oh-fah-TOO-moo-mab |
| Brand name(s), other common name(s) | Arzerra® |
| Drug type | Monoclonal antibody |
| How the drug is given | Intravenously (IV) |
Ofatumumab is FDA approved to treat people who have chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.
Side effects needing medical attention:
Fever; cough; diarrhea; rash; neutropenia (abnormally low white blood count); fatigue; pneumonia; anemia; trouble breathing; nausea; infusion reactions; and upper respiratory tract infection.
For information on how to manage the costs of drug therapy, please see Financial Matters and Prescription Drug Coverage, or to speak with an Information Specialist, call (800) 955-4572.
